HUTCHMED (HCM) and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.
This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.
The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.
The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.
The company also plans to do a phase III confirmatory study of the combination treatment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。